CLINICAL ROLE -
Amgen to Initiate Phase 3 Study of Sotorasib for NSCLC, Based on Results From CodeBreaK 101 Trial
Sotorasib (Lumakras) plus carboplatin and pemetrexed shows promise in the first line treatment of advanced non–small cell lung cancer.
Osimertinib, Chemotherapy Show Survival Benefit for Patients With Advanced, Mutated Lung Cancer
The study met its primary endpoint of progression-free survival, and overall survival is continuing to be evaluated.